Abstract: The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

Abstract: This invention relates to anti-microbial active particles, compositions and uses thereof for inhibiting bacterial growth on surfaces or devices. This invention further discloses methods of making such anti-microbial active particles.

Abstract: An oral care composition with an aqueous phase, hydrophobic phase, active agent, and optionally emulsifier. A jammed emulsion with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier. An oral care composition with aqueous phase, hydrophobic phase, active agent, and optionally emulsifier. Methods of using disclosed compositions for active agent delivery.

Abstract: A cell-penetrating peptide (CPP) comprising comprises a plurality of mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s where a plurality of the amino acids comprise a positively charged guanylurea unit with a small molecule fragment and each of the mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s comprising a drug attached through a linker. The CPP can be used for treating cancers.

Abstract: The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients.

Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.

Abstract: A membrane including a barrier having layers of alginate with different material molar concentrations relative to another material. The layers have a uniform consistency across a thickness of the layers. The thickness is free of laminae and interfaces and forms a single layer morphology that provides permeability for selected molecules.

Abstract: The present disclosure relates to a pharmaceutical solution having a toxicity-reducing effect for anti-tumor drugs, and a pharmaceutical composition comprising the solution as well as a method for using them. The pharmaceutical solution uses deuterium oxide as a solvent.

Abstract: Provided herein are small unilamellar vesicles with surface-displayed polymer moieties, and methods of use and manufacture thereof. In particular, provided herein are polymer-grafted nanobins, and methods of drug delivery therewith.

Abstract: A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

Abstract: An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T1 (b) a denaturing distillation carried out at a temperature T2; wherein steps (a) and (b) may be performed in either order; T1 and T2 are sufficient to cause squalene to boil; T2>T1; and T2>200° C.

Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 50 micrograms to 500 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: Provided herein is a liquid, nonaqueous composition including a pesticide in form of suspended particles, a water soluble solvent, an inorganic thickener, and an alkoxylate. Further provided herein is a method for the preparation of the composition, wherein the pesticide, the water soluble solvent, the inorganic thickener, and the alkoxylate are contacted. Additionally provided herein is a method for controlling phytopathogenic fungi, undesired plant growth, and/or undesired attack by insects or mites, and/or for regulating the growth of plants, wherein the composition acts on the particular pests, their habitat, the plants to be protected from the particular pest, the soil, the undesired plants, the useful plants, and/or the habitat of each plant.

Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: One aspect of the present disclosure is a cosmetic composition containing a solubilized pigment and a method for preparing the same. More specifically, the cosmetic composition containing the solubilized pigment may be prepared through a process of dissolving a pigment in an aqueous phase by dispersing the pigment in the aqueous phase using a pigment dispersing thickener and stabilizing by further increasing the viscosity using a stabilizing thickener. Since the solubilized pigment exhibits dyeing properties similar to dyes, it can be widely applied to various cosmetic compositions.

Abstract: The invention discloses a method for preparing a water-soluble phytosterol nano-dispersion system with intestinal targeted release function, which comprises the following steps: preparing a phytosterol solution; preparing an ethanol aqueous solution containing pectin; then adding zein to obtain a zein pectin solution; mixing the phytosterol solution and the zein pectin solution by means of ultrasonic treatment to obtain a nanoparticle dispersion liquid; rotavaping the nano-particle dispersion liquid to remove ethanol and water to obtain a zein/pectin loaded phytosterol nano-dispersion system. In this invention, not only an ultrasonic method and an anti-solvent method are adopted, but also a pectin component is added with zein as an entrapping agent, which ensures an effective entrapping of phytosterol by zein while further facilitating to form a more compact interface structure and improving a stability of the nano-dispersion system.

Abstract: A multistage colored polymer particle is provided, having a core comprising polymerized units of a monoethylenically unsaturated carboxylic acid core monomer and a non-ionic ethylenically unsaturated core monomer; an inner shell comprising polymerized units of a non-ionic ethylenically unsaturated inner shell monomer; a monoethylenically unsaturated carboxylic acid inner shell monomer; optionally, an aliphatic inner shell monomer; and, optionally, a first polymerizable dye monomer; an outer shell comprising polymerized units of a non-ionic ethylenically unsaturated outer shell monomer; a monoethylenically unsaturated non-carboxylic acid outer shell monomer; optionally, a second polymerizable dye monomer; and, optionally, an aliphatic outer shell monomer; wherein the core, when dry, contains at least one void; and wherein the multistage colored polymer particle comprises polymerized units of polymerizable dye monomer.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: A nanoparticle includes a core. The core includes a bio-resorbable polyester and a hydrophilic polymer. The hydrophilic polymer is a portion of the bio-resorbable polyester or a separate polymer. An acylated human lactoferrin-derived peptide is coated onto the core. The acylated human lactoferrin-derived peptide is a peptide with the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR or an amino acid sequence, which does not differ by more than 8 amino acid positions from the sequence SEQ ID NO: 1. The N-terminus of the human lactoferrin-derived peptide is acylated with a C16-monoacyl group.